SlideShare a Scribd company logo
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy
in Patients With ST-Elevation Myocardial Infarction
TREAT - A Randomized Clinical Trial
JAMA Cardiology March 11, 2018
Dr. Vaibhav Yawalkar
MD, DM Cardiology
IMPORTANCE
The bleeding safety of ticagrelor in patients with ST-
elevation myocardial infarction treated with
fibrinolytic therapy remains uncertain.
OBJECTIVE
To evaluate the short-term safety of ticagrelor when
compared with clopidogrel in patients with ST-
elevation myocardial infarction treated with
fibrinolytic therapy.
DESIGN
A multicenter, randomized, open-label with blinded end point
adjudication trial evaluating non-inferiority of intervention
Enrolled 3799 patients (younger than 75 years) with STEMI
who received fibrinolytic therapy
Place of study: 152 sites from 10 countries
Duration: November 2015 through November 2017
Follow up: 7th day, 30th day, 6 months and 12 months
Prespecified upper boundary for noninferiority, was an
absolute difference of not more than 1.0% for bleeding
episodes
Argentina (06 sites)
Australia (10 sites)
Brazil (25 sites)
New Zealand (07 sites)
Peru (05 sites)
Canada (17 sites)
China (47 sites)
Colombia (02 sites)
Russia (20 sites)
Ukraine (13 sites)
3,799 Patients from 10 Countries
341
27
863
34
55
161
82
293
694
1249
Inclusion Criteria
• Age 18 – 75 years
• STEMI presenting < 24h after symptom onset
• Received fibrinolytic therapy
Exclusion Criteria
• Contraindication to clopidogrel, ticagrelor or fibrinolysis
• Use of oral anticoagulant therapy
• Increased risk of bradycardia (not further defined)
• Concomitant use of a strong CYP3A4 inhibitor/inducer
• Dialysis-dependent
• Clinically-important anemia or thrombocytopenia, or active
bleeding (therefore excluding those who bled early with the
initial fibrinolytic + antiplatelet regimen)
Randomization
Patients were randomly assigned, in a 1:1 ratio to receive
• Ticagrelor with a loading dose of 180 mg
or
• Clopidogrel (with a loading dose of 300 to 600 mg)
As early as possible after Fibrinolysis and not more than
24 hours after fibrinolysis
Randomization
 If randomized to ticagrelor, the trial loading dose (180 mg)
was recommended.
 If randomized to clopidogrel, the patients could receive an
additional 300 mg of clopidogrel at the discretion of the
investigator if undergoing PCI (as 90% patients had already
received loading dose of Clopidogrel after diagnosis of
STEMI) else was directly started on maintenance
Clopidogrel dose.
 The randomized maintenance therapy for Ticagrelor was 90
mg twice daily and for clopidogrel was 75 mg once daily.
 All patients received Acetylsalicylic acid (ASA), 75 to 100 mg
daily, during all the follow-up unless intolerant. For patients not
previously receiving ASA, a loading dose of 162 mg to 325 mg
was given.
 Clopidogrel dose administered before randomization:
> 300 mg (3%)
= 300 mg (87%)
none or < 300 mg (10%)
 Fibrinolytic selection:
TNK ~40%
Alteplase ~20%
Reteplase 17%
other 23%
 Median interval from symptom onset to fibrinolytic
administration = 2.6 hours
 Median interval from fibrinolytic administration to
randomization = 11.4 hours
 PCI during hospitalization was done in 56%, drug-
eluting stent implanted in 34%, no changes in
maintenance dose of either Ticagrelor or Clopidogrel
were made post PCI
Outcome Parameters
Safety outcomes
Primary:
Major bleeding, according to the Thrombolysis in
Myocardial Infarction (TIMI) definition
Secondary:
Major or minor bleeding according to the PLATO
and the Bleeding Academic Research Consortium
(BARC) definitions
Clinically relevant non-major bleeding or minor
bleeding according to the TIMI definition
Outcome Parameters
Secondary Efficacy outcomes
 The composite outcome of death from vascular causes,
MI, or stroke (similar to the PLATO primary outcome)
 Same composite outcome with the addition of recurrent
ischemia, TIA or other arterial thrombotic events
 Individual components of the composite outcome
 All-cause mortality at 30 days
TIMI Definition of Bleeding (Non-CABG related )
Major
• Any intracranial bleeding (excluding microhemorrhages
< 10 mm evident only on gradient echo MRI)
• Clinically overt signs of hemorrhage associated with a drop in hemoglobin of
>5 g/dL
• Fatal bleeding (bleeding that directly results in death within 7 days)
Minor
• Clinically overt (including imaging), resulting in hemoglobin drop of 3 to < 5
g/dL
Requiring medical attention
Any overt sign of hemorrhage that meets one of the following criteria and does not
meet criteria for a major or minor bleeding event
• Requiring intervention (medical or surgical)
• Leading to or prolonging hospitalization
• Prompting evaluation (leading to an unscheduled visit to a healthcare
professional and diagnostic testing, either laboratory or imaging)
Minimal
• Any overt bleeding event that does not meet the criteria above
 The mean (SD) age was 58.0 (9.5) years
 77.1% were men
 46.3% were current smokers
 8.6% had a history of MI.
 99.9% of the patients received fibrinolytic agent, of whom
75.9% received a fibrin specific agent
 The 2 treatment groups were well balanced as
demonstrated by the baseline characteristics
Baseline characteristics
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Results: (At 30 days)
Bleeding
 The primary outcome (TIMI major bleeding up to 30 days)
occurred in
14 of 1913 patients (0.73%) in the ticagrelor group and
13 of 1886 patients (0.69%) in the clopidogrel group
(absolute difference,0.04%; 95%CI,- 0.49% to 0.58%;
P < .001 for noninferiority)
 Major bleeding as assessed by the PLATO criteria and
BARC types 3 to 5 bleeding occurred in
23 of 1913 patients (1.20%) in the ticagrelor group and
26 of 1886 patients (1.38%) in the clopidogrel group
(absolute difference, -0.18%; 95% CI, -0.89% to 0.54%;
P = .001 for noninferiority)
 The rates of fatal bleeding (0.16 % vs 0.11%; P = .67) and
intracranial bleeding (0.42% vs 0.37%; P = .82) were similar
between the ticagrelor and the clopidogrel groups,
respectively.
 Minor and minimal bleeding, as well as total bleeding, were
more common with ticagrelor than with clopidogrel,
irrespective of the classification used
Results: (At 30 days)
Bleeding
 In patients who received study drugs within 4 hours after
initiation of fibrinolytic therapy, the TIMI major bleeding
events rates in both groups were more compared to those
who received drugs after 4 hours.
< 4 hours : 1.5% vs 1.2%
4 – 8 hours: 0.8% vs 1.2%
8 - 16hours: 0.5% vs 0.3%
16+ hours: 0.5% vs 0.2%
(Ticagrelor vs Clopidogrel)
Results: (At 30 days)
Bleeding
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Results: (At 30 days)
Efficacy
 The composite outcome of death from vascular causes, MI,
or stroke occurred in
76 patients (4.0%) treated with ticagrelor and in
82 patients (4.3%) receiving clopidogrel
(hazard ratio, 0.91; 95%CI, 0.67- 1.25; P = 0.57).
 The rates of individual outcomes of MI, stroke, and other
arterial thrombotic events were similar in the ticagrelor and
clopidogrel groups.
Results: (At 30 days)
Other adverse Events
 Discontinuation of the study drug owing to serious adverse
events was similar between ticagrelor and clopidogrel
groups (0.40% vs 0.40%; P = .99).
 Dyspnea was more common in the ticagrelor group than in
the clopidogrel group [13.9%] vs [7.6%] respectively
 Few patients discontinued the study drug because of
dyspnea (19 of 1913 patients [1.0%] in the ticagrelor group
and none in the clopidogrel group).
 The frequencies of serious adverse events were similar
between groups.
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology
Discussion
 In this trial of patients younger than 75 years with STEMI
who received fibrinolytic therapy as their initial reperfusion
strategy, delayed administration of ticagrelor was noninferior
to clopidogrel with respect to major bleeding (according to
the TIMI, PLATO, and BARC classifications) at 30 days.
 “Delayed” here meaning that, Ticagrelor was not used as
primary antiplatelet to be given after diagnosis of STEMI,
rather was given soon after & within 24 hours of fibrinolysis.
Clopidogrel was the primary antiplatelet received by 90% of
patients.
 The rates of fatal and intracranial bleeding were similar
between the Ticagrelor and Clopidogrel groups.
Discussion
 In contrast the rates of minor, minimal , and total bleeding
events were numerically higher with ticagrelor than with
clopidogrel.
 Because most of the included patients were pretreated with
clopidogrel, these findings reflect mostly the noninferiority of
switching from clopidogrel to ticagrelor in patients already
treated with clopidogrel.
Other Trials
 A trial by Dehghani et al compared ticagrelor with clopidogrel
in 144 patients undergoing early PCI post-reperfusion with
tenectaplase.
 All patients received clopidogrel pre randomization, and the
median time of thrombolytic administration to randomization
(and initiation of ticagrelor vs clopidogrel) was about 6 hours.
 The BARC types 3 to 5 bleeding rates at 30 days were 1.3%
in both the ticagrelor and clopidogrel groups at 30 days,
which are similar to the rates observed in TREAT for the
same outcome
Other Trials
 The Sampling P2Y12 Receptor Inhibition With Prasugrel and
Ticagrelor in Patients Submitted to Thrombolysis (SAMPA)
trial compared ticagrelor and prasugrel in patients with
STEMI post-fibrinolytic therapy.
 Similar to TREAT, all patients also received clopidogrel pre-
randomization, and the median time to randomization after
thrombolytic therapy was 12.2 hours.
 No major bleeding events were observed within 30 days
Limitations
 Comparisons of safety event rates between TREAT and
other large-scale ticagrelor trials in patients with acute
coronary syndromes are limited owing to differences in study
designs, populations, and follow-up.
 Noninferiority margin of 1% could be quite wide and
reflective of the modest sample size.
 Owing to the low number of events, statistical power to
assess superiority is limited; thus, these findings must be
interpreted as exploratory.
Limitations
 The median time of thrombolytic administration to
randomization was about 11 hours, which is beyond the half-
life of fibrin-specific fibrinolytics. Thus, it is likely that patients
who had early bleeding events associated with fibrinolytic
therapy were excluded.
 Trial does not address treatment of patients older than 75
years, who were excluded.
 The crucial question that needs to be addressed—
concomitant use of ticagrelor with lytic therapy for acute
revascularization— remains unanswered in this trial.
Conclusions
 Given that patients who received fibrinolytic therapy in the
previous 24 hours were excluded from the PLATO trial and
STEMI guidelines recommend that ticagrelor should only be
initiated after 48 hours after fibrinolysis, this trial adds new
safety information for Ticagrelor for early use after
fibrinolysis.
 In patients younger than 75 years with STEMI, delayed
administration of ticagrelor after fibrinolytic therapy was
noninferior to clopidogrel for TIMI major bleeding at 30 days.
However, minor bleeding was increased with ticagrelor, and
there was no benefit on efficacy outcomes.
Bottom line:
 In patients < 75 years who received fibrinolytic therapy
plus a loading dose of clopidogrel for STEMI & already
not actively bleeding from this, switching to ticagrelor with
a loading dose 8 - 24hours after administration of the
fibrinolytic agent does not appear to increase the risk of
major, fatal or intracranial bleeding at 30 days versus
continuing with clopidogrel.
 Follow-up in TREAT is ongoing; 12-month outcomes as
well as meta-analysis with PLATO STEMI subgroup will
likely be reported in 2019.
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction  by Dr. Vaibhav Yawalkar MD, DM Cardiology

More Related Content

PPTX
Statins: Friend or foe?
PPTX
Ticagrelor or prasugrel in patients with acute coronary
PPTX
DELIVER delivered 2022.pptx
PPTX
Plato trial
PPTX
Antiplatelet therapy
PPTX
PPTX
PCKS9 INHIBITORS
PDF
De-escalation of P2Y12 Inhibitors - Dr. Aradi
Statins: Friend or foe?
Ticagrelor or prasugrel in patients with acute coronary
DELIVER delivered 2022.pptx
Plato trial
Antiplatelet therapy
PCKS9 INHIBITORS
De-escalation of P2Y12 Inhibitors - Dr. Aradi

What's hot (20)

PDF
TRITON-TIMI 38 trial - Summary & Results
DOCX
AFFIRM trial JC NOVANT
PPTX
DAPT trial
PPTX
Sglt 2 inhibiors in cardiovascular diseases
PPTX
clopidogrel (old is gold)
PPTX
PPTX
Ticagrelor in acute myocardial infarction
PPTX
Management strategy in HF with ARNI - Recent updates
PPTX
Strong HF trial ppt.pptx
PPTX
Role of SGLT2i in cardio-renal protection
PPT
Crestor Presentation
PPTX
Ticagrelor
PPTX
Acute Coronary Syndrome
PPT
Dyslipidemia management an evidence based approach
PPT
Strategies for the use of cardioselective beta blockers in cv continuum
PDF
Residual CV risk: what is this? Role of lipids and inflammation and how to id...
PPTX
Acs focus on dapt
PPTX
SGLT2 inhibitor trials
PPTX
Pioneer hf
PPTX
Paradigm HF trial
TRITON-TIMI 38 trial - Summary & Results
AFFIRM trial JC NOVANT
DAPT trial
Sglt 2 inhibiors in cardiovascular diseases
clopidogrel (old is gold)
Ticagrelor in acute myocardial infarction
Management strategy in HF with ARNI - Recent updates
Strong HF trial ppt.pptx
Role of SGLT2i in cardio-renal protection
Crestor Presentation
Ticagrelor
Acute Coronary Syndrome
Dyslipidemia management an evidence based approach
Strategies for the use of cardioselective beta blockers in cv continuum
Residual CV risk: what is this? Role of lipids and inflammation and how to id...
Acs focus on dapt
SGLT2 inhibitor trials
Pioneer hf
Paradigm HF trial
Ad

Similar to Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction by Dr. Vaibhav Yawalkar MD, DM Cardiology (20)

PPTX
SYMCARD - Antiplatelet in ACS.pptx
PPTX
Ticagrelor PROPERTIES AND TRIALS
PDF
Role of More Potent Antiplatelet in ACS Management
PPTX
Journal-Club-final-1
PPT
2017 dapt slide set2
PDF
Ticagrelor.pdf
PPTX
Drug that has changed the trends a presentation.
PPTX
journal club- dual-antiplatelets therapy Post AMI
PDF
Journal Article Analysis: Ticagrelor versus Clopidogrel in ACS (PLATO)
PPTX
CONTROVERSIES FOR ASIAN PATIENTS
PPTX
12 Reasons to Prescribe Ticagrelor & Affordability of Generics.pptx
PPT
PLATO TRIAL, A RANDOMIZED CONTROLLED TRIAL PUBLISHED IN NEW ENGLAND JOURNAL
PPTX
Antiplatelet agents in acute coronary syndrome
PPTX
TALOS Ami ticagrelor vs clopidrogrel in acute myocardial infarction
PPTX
Twilight trila journal club
PPT
PLATO (Platelet Inhibition and Patient Outcomes)
PPTX
Antiplatelets and anticoagulation in AMI
PPTX
Triton timi 38
PDF
New Option of Antiplatelet and Controversies in ACS Treatment
PPTX
twilight ppt.pptx
SYMCARD - Antiplatelet in ACS.pptx
Ticagrelor PROPERTIES AND TRIALS
Role of More Potent Antiplatelet in ACS Management
Journal-Club-final-1
2017 dapt slide set2
Ticagrelor.pdf
Drug that has changed the trends a presentation.
journal club- dual-antiplatelets therapy Post AMI
Journal Article Analysis: Ticagrelor versus Clopidogrel in ACS (PLATO)
CONTROVERSIES FOR ASIAN PATIENTS
12 Reasons to Prescribe Ticagrelor & Affordability of Generics.pptx
PLATO TRIAL, A RANDOMIZED CONTROLLED TRIAL PUBLISHED IN NEW ENGLAND JOURNAL
Antiplatelet agents in acute coronary syndrome
TALOS Ami ticagrelor vs clopidrogrel in acute myocardial infarction
Twilight trila journal club
PLATO (Platelet Inhibition and Patient Outcomes)
Antiplatelets and anticoagulation in AMI
Triton timi 38
New Option of Antiplatelet and Controversies in ACS Treatment
twilight ppt.pptx
Ad

More from vaibhavyawalkar (20)

PPTX
Low carbohydrate and high fat diet by Dr. Vaibhav Yawalkar, MD DM Cardiology,...
PPTX
Hypertension in pregnancy by Dr. Vaibhav Yawalkar MD DM Cardiology, Consultan...
PPTX
His bundle pacing by Dr. Vaibhav Yawalkar MD DM Cardiology, Consultant Interv...
PPTX
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
PPTX
Cardiogenic shock 2019 update by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
PPTX
Heart Failure : what is new by Dr. Vaibhav Yawalkar MD DM Cardiology, Consult...
PPTX
Cad and ckd by Dr. Vaibhav Yawalkar MD DM Cardiology, Consultant Intervention...
PPTX
Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...
PPTX
Pulmonary embolism - 2019 ESC Guidelines by Dr. Vaibhav Yawalkar MD DM Cardio...
PPT
Heart Failure with Preserved Ejection Fraction By DR. Vaibhav Yawalkar
PPTX
Low carbohydrate high fat diet (LCHF), What should we advise ? by Dr. Vaibhav...
PPTX
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
PPTX
A Practical Approach to the Management of Complications During Percutaneous C...
PPTX
SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...
PPTX
Right Ventricle Anatomy, Physiology & ECHO Assessment by Dr. Vaibhav Yawalka...
PPTX
Heart failure and liver dysfunction By Dr. Vaibhav Yawalkar MD,DM Cardiology
PPTX
Cardiac electrophysiology by Dr. Vaibhav Yawalkar , MD,DM Cardiology
PPTX
Mechanism of cardiac contraction dr vaibhav yawalkar
PPTX
Dextrocardia By Dr. Vaibhav Yawalkar
PPTX
CT imaging of Brain in Clinical Practice by Dr. Vaibhav Yawalkar
Low carbohydrate and high fat diet by Dr. Vaibhav Yawalkar, MD DM Cardiology,...
Hypertension in pregnancy by Dr. Vaibhav Yawalkar MD DM Cardiology, Consultan...
His bundle pacing by Dr. Vaibhav Yawalkar MD DM Cardiology, Consultant Interv...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Cardiogenic shock 2019 update by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Heart Failure : what is new by Dr. Vaibhav Yawalkar MD DM Cardiology, Consult...
Cad and ckd by Dr. Vaibhav Yawalkar MD DM Cardiology, Consultant Intervention...
Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...
Pulmonary embolism - 2019 ESC Guidelines by Dr. Vaibhav Yawalkar MD DM Cardio...
Heart Failure with Preserved Ejection Fraction By DR. Vaibhav Yawalkar
Low carbohydrate high fat diet (LCHF), What should we advise ? by Dr. Vaibhav...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
A Practical Approach to the Management of Complications During Percutaneous C...
SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...
Right Ventricle Anatomy, Physiology & ECHO Assessment by Dr. Vaibhav Yawalka...
Heart failure and liver dysfunction By Dr. Vaibhav Yawalkar MD,DM Cardiology
Cardiac electrophysiology by Dr. Vaibhav Yawalkar , MD,DM Cardiology
Mechanism of cardiac contraction dr vaibhav yawalkar
Dextrocardia By Dr. Vaibhav Yawalkar
CT imaging of Brain in Clinical Practice by Dr. Vaibhav Yawalkar

Recently uploaded (20)

PPT
Rheumatology Member of Royal College of Physicians.ppt
PDF
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
PPTX
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
PPTX
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
PPTX
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
PDF
Copy of OB - Exam #2 Study Guide. pdf
PPTX
Acute Coronary Syndrome for Cardiology Conference
PDF
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
PPT
Dermatology for member of royalcollege.ppt
PDF
شيت_عطا_0000000000000000000000000000.pdf
PPT
nephrology MRCP - Member of Royal College of Physicians ppt
PPTX
09. Diabetes in Pregnancy/ gestational.pptx
PPTX
Electrolyte Disturbance in Paediatric - Nitthi.pptx
PDF
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
PPT
Infections Member of Royal College of Physicians.ppt
PDF
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
PDF
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
PDF
Calcified coronary lesions management tips and tricks
PPTX
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
PDF
Lecture 8- Cornea and Sclera .pdf 5tg year
Rheumatology Member of Royal College of Physicians.ppt
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
Copy of OB - Exam #2 Study Guide. pdf
Acute Coronary Syndrome for Cardiology Conference
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
Dermatology for member of royalcollege.ppt
شيت_عطا_0000000000000000000000000000.pdf
nephrology MRCP - Member of Royal College of Physicians ppt
09. Diabetes in Pregnancy/ gestational.pptx
Electrolyte Disturbance in Paediatric - Nitthi.pptx
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
Infections Member of Royal College of Physicians.ppt
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
Calcified coronary lesions management tips and tricks
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
Lecture 8- Cornea and Sclera .pdf 5tg year

Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction by Dr. Vaibhav Yawalkar MD, DM Cardiology

  • 1. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction TREAT - A Randomized Clinical Trial JAMA Cardiology March 11, 2018 Dr. Vaibhav Yawalkar MD, DM Cardiology
  • 2. IMPORTANCE The bleeding safety of ticagrelor in patients with ST- elevation myocardial infarction treated with fibrinolytic therapy remains uncertain. OBJECTIVE To evaluate the short-term safety of ticagrelor when compared with clopidogrel in patients with ST- elevation myocardial infarction treated with fibrinolytic therapy.
  • 3. DESIGN A multicenter, randomized, open-label with blinded end point adjudication trial evaluating non-inferiority of intervention Enrolled 3799 patients (younger than 75 years) with STEMI who received fibrinolytic therapy Place of study: 152 sites from 10 countries Duration: November 2015 through November 2017 Follow up: 7th day, 30th day, 6 months and 12 months Prespecified upper boundary for noninferiority, was an absolute difference of not more than 1.0% for bleeding episodes
  • 4. Argentina (06 sites) Australia (10 sites) Brazil (25 sites) New Zealand (07 sites) Peru (05 sites) Canada (17 sites) China (47 sites) Colombia (02 sites) Russia (20 sites) Ukraine (13 sites) 3,799 Patients from 10 Countries 341 27 863 34 55 161 82 293 694 1249
  • 5. Inclusion Criteria • Age 18 – 75 years • STEMI presenting < 24h after symptom onset • Received fibrinolytic therapy Exclusion Criteria • Contraindication to clopidogrel, ticagrelor or fibrinolysis • Use of oral anticoagulant therapy • Increased risk of bradycardia (not further defined) • Concomitant use of a strong CYP3A4 inhibitor/inducer • Dialysis-dependent • Clinically-important anemia or thrombocytopenia, or active bleeding (therefore excluding those who bled early with the initial fibrinolytic + antiplatelet regimen)
  • 6. Randomization Patients were randomly assigned, in a 1:1 ratio to receive • Ticagrelor with a loading dose of 180 mg or • Clopidogrel (with a loading dose of 300 to 600 mg) As early as possible after Fibrinolysis and not more than 24 hours after fibrinolysis
  • 7. Randomization  If randomized to ticagrelor, the trial loading dose (180 mg) was recommended.  If randomized to clopidogrel, the patients could receive an additional 300 mg of clopidogrel at the discretion of the investigator if undergoing PCI (as 90% patients had already received loading dose of Clopidogrel after diagnosis of STEMI) else was directly started on maintenance Clopidogrel dose.  The randomized maintenance therapy for Ticagrelor was 90 mg twice daily and for clopidogrel was 75 mg once daily.
  • 8.  All patients received Acetylsalicylic acid (ASA), 75 to 100 mg daily, during all the follow-up unless intolerant. For patients not previously receiving ASA, a loading dose of 162 mg to 325 mg was given.  Clopidogrel dose administered before randomization: > 300 mg (3%) = 300 mg (87%) none or < 300 mg (10%)  Fibrinolytic selection: TNK ~40% Alteplase ~20% Reteplase 17% other 23%
  • 9.  Median interval from symptom onset to fibrinolytic administration = 2.6 hours  Median interval from fibrinolytic administration to randomization = 11.4 hours  PCI during hospitalization was done in 56%, drug- eluting stent implanted in 34%, no changes in maintenance dose of either Ticagrelor or Clopidogrel were made post PCI
  • 10. Outcome Parameters Safety outcomes Primary: Major bleeding, according to the Thrombolysis in Myocardial Infarction (TIMI) definition Secondary: Major or minor bleeding according to the PLATO and the Bleeding Academic Research Consortium (BARC) definitions Clinically relevant non-major bleeding or minor bleeding according to the TIMI definition
  • 11. Outcome Parameters Secondary Efficacy outcomes  The composite outcome of death from vascular causes, MI, or stroke (similar to the PLATO primary outcome)  Same composite outcome with the addition of recurrent ischemia, TIA or other arterial thrombotic events  Individual components of the composite outcome  All-cause mortality at 30 days
  • 12. TIMI Definition of Bleeding (Non-CABG related ) Major • Any intracranial bleeding (excluding microhemorrhages < 10 mm evident only on gradient echo MRI) • Clinically overt signs of hemorrhage associated with a drop in hemoglobin of >5 g/dL • Fatal bleeding (bleeding that directly results in death within 7 days) Minor • Clinically overt (including imaging), resulting in hemoglobin drop of 3 to < 5 g/dL Requiring medical attention Any overt sign of hemorrhage that meets one of the following criteria and does not meet criteria for a major or minor bleeding event • Requiring intervention (medical or surgical) • Leading to or prolonging hospitalization • Prompting evaluation (leading to an unscheduled visit to a healthcare professional and diagnostic testing, either laboratory or imaging) Minimal • Any overt bleeding event that does not meet the criteria above
  • 13.  The mean (SD) age was 58.0 (9.5) years  77.1% were men  46.3% were current smokers  8.6% had a history of MI.  99.9% of the patients received fibrinolytic agent, of whom 75.9% received a fibrin specific agent  The 2 treatment groups were well balanced as demonstrated by the baseline characteristics Baseline characteristics
  • 18. Results: (At 30 days) Bleeding  The primary outcome (TIMI major bleeding up to 30 days) occurred in 14 of 1913 patients (0.73%) in the ticagrelor group and 13 of 1886 patients (0.69%) in the clopidogrel group (absolute difference,0.04%; 95%CI,- 0.49% to 0.58%; P < .001 for noninferiority)  Major bleeding as assessed by the PLATO criteria and BARC types 3 to 5 bleeding occurred in 23 of 1913 patients (1.20%) in the ticagrelor group and 26 of 1886 patients (1.38%) in the clopidogrel group (absolute difference, -0.18%; 95% CI, -0.89% to 0.54%; P = .001 for noninferiority)
  • 19.  The rates of fatal bleeding (0.16 % vs 0.11%; P = .67) and intracranial bleeding (0.42% vs 0.37%; P = .82) were similar between the ticagrelor and the clopidogrel groups, respectively.  Minor and minimal bleeding, as well as total bleeding, were more common with ticagrelor than with clopidogrel, irrespective of the classification used Results: (At 30 days) Bleeding
  • 20.  In patients who received study drugs within 4 hours after initiation of fibrinolytic therapy, the TIMI major bleeding events rates in both groups were more compared to those who received drugs after 4 hours. < 4 hours : 1.5% vs 1.2% 4 – 8 hours: 0.8% vs 1.2% 8 - 16hours: 0.5% vs 0.3% 16+ hours: 0.5% vs 0.2% (Ticagrelor vs Clopidogrel) Results: (At 30 days) Bleeding
  • 24. Results: (At 30 days) Efficacy  The composite outcome of death from vascular causes, MI, or stroke occurred in 76 patients (4.0%) treated with ticagrelor and in 82 patients (4.3%) receiving clopidogrel (hazard ratio, 0.91; 95%CI, 0.67- 1.25; P = 0.57).  The rates of individual outcomes of MI, stroke, and other arterial thrombotic events were similar in the ticagrelor and clopidogrel groups.
  • 25. Results: (At 30 days) Other adverse Events  Discontinuation of the study drug owing to serious adverse events was similar between ticagrelor and clopidogrel groups (0.40% vs 0.40%; P = .99).  Dyspnea was more common in the ticagrelor group than in the clopidogrel group [13.9%] vs [7.6%] respectively  Few patients discontinued the study drug because of dyspnea (19 of 1913 patients [1.0%] in the ticagrelor group and none in the clopidogrel group).  The frequencies of serious adverse events were similar between groups.
  • 28. Discussion  In this trial of patients younger than 75 years with STEMI who received fibrinolytic therapy as their initial reperfusion strategy, delayed administration of ticagrelor was noninferior to clopidogrel with respect to major bleeding (according to the TIMI, PLATO, and BARC classifications) at 30 days.  “Delayed” here meaning that, Ticagrelor was not used as primary antiplatelet to be given after diagnosis of STEMI, rather was given soon after & within 24 hours of fibrinolysis. Clopidogrel was the primary antiplatelet received by 90% of patients.  The rates of fatal and intracranial bleeding were similar between the Ticagrelor and Clopidogrel groups.
  • 29. Discussion  In contrast the rates of minor, minimal , and total bleeding events were numerically higher with ticagrelor than with clopidogrel.  Because most of the included patients were pretreated with clopidogrel, these findings reflect mostly the noninferiority of switching from clopidogrel to ticagrelor in patients already treated with clopidogrel.
  • 30. Other Trials  A trial by Dehghani et al compared ticagrelor with clopidogrel in 144 patients undergoing early PCI post-reperfusion with tenectaplase.  All patients received clopidogrel pre randomization, and the median time of thrombolytic administration to randomization (and initiation of ticagrelor vs clopidogrel) was about 6 hours.  The BARC types 3 to 5 bleeding rates at 30 days were 1.3% in both the ticagrelor and clopidogrel groups at 30 days, which are similar to the rates observed in TREAT for the same outcome
  • 31. Other Trials  The Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis (SAMPA) trial compared ticagrelor and prasugrel in patients with STEMI post-fibrinolytic therapy.  Similar to TREAT, all patients also received clopidogrel pre- randomization, and the median time to randomization after thrombolytic therapy was 12.2 hours.  No major bleeding events were observed within 30 days
  • 32. Limitations  Comparisons of safety event rates between TREAT and other large-scale ticagrelor trials in patients with acute coronary syndromes are limited owing to differences in study designs, populations, and follow-up.  Noninferiority margin of 1% could be quite wide and reflective of the modest sample size.  Owing to the low number of events, statistical power to assess superiority is limited; thus, these findings must be interpreted as exploratory.
  • 33. Limitations  The median time of thrombolytic administration to randomization was about 11 hours, which is beyond the half- life of fibrin-specific fibrinolytics. Thus, it is likely that patients who had early bleeding events associated with fibrinolytic therapy were excluded.  Trial does not address treatment of patients older than 75 years, who were excluded.  The crucial question that needs to be addressed— concomitant use of ticagrelor with lytic therapy for acute revascularization— remains unanswered in this trial.
  • 34. Conclusions  Given that patients who received fibrinolytic therapy in the previous 24 hours were excluded from the PLATO trial and STEMI guidelines recommend that ticagrelor should only be initiated after 48 hours after fibrinolysis, this trial adds new safety information for Ticagrelor for early use after fibrinolysis.  In patients younger than 75 years with STEMI, delayed administration of ticagrelor after fibrinolytic therapy was noninferior to clopidogrel for TIMI major bleeding at 30 days. However, minor bleeding was increased with ticagrelor, and there was no benefit on efficacy outcomes.
  • 35. Bottom line:  In patients < 75 years who received fibrinolytic therapy plus a loading dose of clopidogrel for STEMI & already not actively bleeding from this, switching to ticagrelor with a loading dose 8 - 24hours after administration of the fibrinolytic agent does not appear to increase the risk of major, fatal or intracranial bleeding at 30 days versus continuing with clopidogrel.  Follow-up in TREAT is ongoing; 12-month outcomes as well as meta-analysis with PLATO STEMI subgroup will likely be reported in 2019.